Skip to main content
. 2022 Oct 20;40(1):194–210. doi: 10.1007/s12325-022-02332-w

Fig. 2.

Fig. 2

Deterministic sensitivity analyses. Base case: Moderate-to-severe SLE was defined as BILAG-2004 ≥ 20 or SLEDAI-2K ≥ 10; Clinical response was based on the SRI-4; 2-year payer perspective. BILAG British Isles Lupus Assessment Group, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-years, SLE systemic lupus erythematosus, SLEDAI-2K SLE Disease Activity Index 2000, SoC standard of care, SRI-4 SLE Responder Index